Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

119 results about "Fatty acid synthase" patented technology

Fatty acid synthase (FAS) is an enzyme that in humans is encoded by the FASN gene. Fatty acid synthase is a multi-enzyme protein that catalyzes fatty acid synthesis. It is not a single enzyme but a whole enzymatic system composed of two identical 272 kDa multifunctional polypeptides, in which substrates are handed from one functional domain to the next.

Polyunsaturated fatty acid production in heterologous organisms using PUFA polyketide synthase systems

Disclosed are novel acyl-CoA synthetases and novel acyltransferases, nucleic acid molecules encoding the same, recombinant nucleic acid molecules and recombinant host cells comprising such nucleic acid molecules, genetically modified organisms (microorganisms and plants) comprising the same, and methods of making and using the same. Also disclosed are genetically modified organisms (e.g., plants, microorganisms) that have been genetically modified to express a PKS-like system for the production of PUFAs (a PUFA PKS system or PUFA synthase), wherein the organisms have been modified to express an acyl-CoA synthetase, to express an acyl transferase, to delete or inactivate a fatty acid synthase (FAS) expressed by the organism, to reduce competition for malonyl CoA with the PUFA synthase or to increase the level of malonyl CoA in the plant or plant cell, and in one aspect, to inhibit KASII or KASIII. Additional modifications, and methods to make and use such organisms, in addition to PUFAs and oils obtained from such organisms, are disclosed, alone with various products including such PUFAs and oils.
Owner:SEMBIOSYS GENETICS INC +1

Novel antagonists of the human fatty acid synthase thioesterase

The present invention provides for compounds of formula (I)-(XIII), as well as pharmaceutically acceptable salts thereof, metabolites thereof, pro-drugs thereof, and pharmaceutical kits that include such compounds. The present invention also provides for the compounds of formula (I)-(XIII) for use in medical therapy or diagnosis. The present invention also provides for the use of the compounds of formula (I)-(XIII) in treating cancer in mammals (e.g., humans), as well inhibiting tumor cell growth in such mammals. The present invention also provides for methods of inhibiting FAS. The methods include contacting FAS with an effective amount of a compound of formula (I)-(XIII). The present invention also provides for methods of inhibiting the TE domain of the FAS. The methods include contacting the thioesterase TE domain of the FAS with an effective amount of a compound of formula (I)-(XIII). The present invention also provides for methods of treating cancer in mammals, as well as methods of inhibiting tumor cell growth in such mammals. The methods include administering a compound of formula (I)-(XIII) to a mammal in need of such treatment.
Owner:BURNHAM INST THE

Polyunsaturated fatty acid production in heterologous organisms using pufa polyketide synthase systems

Disclosed are novel acyl-CoA synthetases and novel acyltransferases, nucleic acid molecules encoding the same, recombinant nucleic acid molecules and recombinant host cells comprising such nucleic acid molecules, genetically modified organisms (microorganisms and plants) comprising the same, and methods of making and using the same. Also disclosed are genetically modified organisms (e.g., plants, microorganisms) that have been genetically modified to express a PKS-like system for the production of PUFAs (a PUFA PKS system or PUFA synthase), wherein the organisms have been modified to express an acyl-CoA synthetase, to express an acyl transferase, to delete or inactivate a fatty acid synthase (FAS) expressed by the organism, to reduce competition for malonyl CoA with the PUFA synthase or to increase the level of malonyl CoA in the organism, and in one aspect, to inhibit KASII or KASIII. Additional modifications, and methods to make and use such organisms, in addition to PUFAs and oils obtained from such organisms, are disclosed, alone with various products including such PUFAs and oils.
Owner:DSM IP ASSETS BV

Metabolically engineered cells for the production of polyunsaturated fatty acids

The present invention relates to the construction and engineering of cells, more particularly microorganisms for producing PUFAs with four or more double bonds from non-fatty acid substrates through heterologous expression of an oxygen requiring pathway. The invention especially involves improvement of the PUFA content in the host organism through fermentation optimization, e.g. decreasing the temperature and / or designing an optimal medium, or through improving the flux towards fatty acids by metabolic engineering, e.g. through over-expression of fatty acid synthases, over-expression of other enzymes involved in biosynthesis of the precursors for PUFAs, or codon optimization of the heterologous genes, or expression of heterologous enzymes involved in the biosynthesis of the precursor for PUFAs.
Owner:FLUXOME SCI AS

Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer

A pharmaceutical combination product is disclosed that comprises a receptor tyrosine kinase inhibitor and a fatty acid synthase inhibitor, and to the use thereof in the manufacture of a medicament for use in the treatment or prophylaxis of cancer.
Owner:WYETH

Therapeutic Agents - 551

A compound of formula Ior a pharmaceutically acceptable salt thereof, processes for preparing such compounds, their use as Fatty Acid Synthase inhibitors, methods for their therapeutic use, particularly in the treatment of obesity, diabetes mellitus, cancer and infection and pharmaceutical compositions containing them.
Owner:ASTRAZENECA AB

Polyunsaturated fatty acid production in heterologous organisms using pufa polyketide synthase systems

Disclosed are novel acyl-CoA synthetases and novel acyltransferases, nucleic acid molecules encoding the same, recombinant nucleic acid molecules and recombinant host cells comprising such nucleic acid molecules, genetically modified organisms (microorganisms and plants) comprising the same, and methods of making and using the same. Also disclosed are genetically modified organisms (e.g., plants, microorganisms) that have been genetically modified to express a PKS-like system for the production of PUFAs (a PUFA PKS system or PUFA synthase), wherein the organisms have been modified to express an acyl-CoA synthetase, to express an acyl transferase, to delete or inactivate a fatty acid synthase (FAS) expressed by the organism, to reduce competition for malonyl CoA with the PUFA synthase or toincrease the level of malonyl CoA in the organism, and in one aspect, to inhibit KASII or KASIII. Additional modifications, and methods to make and use such organisms, in addition to PUFAs and oils o btained from such organisms, are disclosed, alone with various products including such PUFAs and oils.
Owner:DSM IP ASSETS BV

3-methoxylflavonoid compound, preparation method and application thereof

A 3-methoxy-flavone compound comprises 5,7-dihydroxy-8-(3,3-dimethyl diallyl)-3,3', 4'-trimethoxy flavone and 5, 7-2 dihydroxy-8- (3,3-dimethyl allyl)-3,4'-dimethoxy flavonoe. harmacological test results prove that: the 3-methoxy-flavone compound is an effective fatty acid synthase inhibitor, which shows the broad-spectrum anti-tumor effect in the cytotoxicity tests of various tumor cell lines and has strong tumor growth inhibiting effect on human prostate cancer cell LnCAP, human breast cancer cell ZR-75-1, human lung cancer cell NCI-H23 or human colon cancer cell HCT-116 when applied to human tumor transplant nude mice model tests. In addition, the 3-methoxy-flavone compound reveals no toxicity in mice acute toxicity tests, which then can be used as anti-tumor drug and is a new broad-spectrum anti-tumor drug with great development prospects.
Owner:殷正丰 +2

Kiwi Extract

The invention describes the preparation, isolation and use of an extract of kiwi fruit for the treatment of a disease or condition related with, caused by or mediated by activity of human pancreatic lipase and / or human fatty acid synthase.
Owner:OMNICA

Cancer-specific promoters

The present invention regards cancer-specific control sequences that direct expression of a polynucleotide encoding a therapeutic gene product for treatment of the cancer. Specifically, the invention encompasses breast cancer-specific and ovarian cancer-specific control sequences. Two breast cancer-specific sequences utilize specific regions of fatty acid synthase and claudin 4 promoters, particularly in combination with a two-step transcription amplification sequence and / or a post-transcriptional control sequence. Two ovarian cancer-specific sequences utilize specific regions of hTERT and survivin promoters, particularly in combination with a two-step transcription amplification sequence and / or a post-transcriptional control sequence. In more particular embodiments, these polynucleotides are administered in combination with liposomes.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Novel Polyhydroxylated Compounds as Fatty Acid Synthase (FASN) Inhibitors

The present invention relates to new polyhydroxylated compounds and, in particular, to its activity as fatty acid synthase (FASN) inhibitors and to their use for the treatment of pathological states for which an inhibitor of this enzyme is indicated. The invention further relate to pharmaceutical compositions containing them and to a process for the preparation of such compounds.
Owner:FUNDACIO PRIVADA INST DINVESTIGACIO BIOMEDICA DE GIRONA DR JOSEP TRUETA +1

Pharmaceutical Composition Comprising Metadoxine and Garlic Oil For Preventing and Treating Alcohol-Induced Fatty Liver and Steatohepatitis

InactiveUS20100062090A1Effective treatmentPrevent hepatitisBiocideOrganic active ingredientsTG - TriglycerideMetadoxine
Provided is a pharmaceutical or food or drink composition for preventing or treating alcohol-induced fatty liver or steatohepatitis comprising metadoxine (pyridoxol 1-2-pyrrolidone-5-carboxylate) and garlic oil as active ingredients. The concurrent administration of metadoxine and garlic oil according to the present invention exhibits outstandingly superior effects of inhibiting the accumulation of triglyceride and increase of blood AST (aspartate aminotransferase) level in liver el tissue, inhibiting the expression of FAS (fatty acid synthase), CYP2E1 and iNOS (inducible nitric oxide synthase) and inhibiting the deactivation of AMPK (AMP-activated protein kinase), as compared to the administration of metadoxine or garlic oil only.
Owner:SEOUL NAT UNIV R&DB FOUND

Method for inhibiting cancer development by fatty acid synthase inhibitors

A method for inhibiting or preventing cancer development by the administration of fatty acid synthase (FAS) inhibitors. In particular, the present invention prohibits or delays the development of invasive cancer from pre-malignant (non-invasive) lesions that express FAS. Compositions containing FAS inhibitors also are provided, as well as methods for administering the FAS inhibitors and compositions to patients in need thereof.
Owner:FASGEN +1

Extract of yangtao actinidia root and preparation method and applications thereof

The invention discloses an extract of yangtao actinidia root and a preparation method and applications thereof. The extract of yangtao actinidia root, which is provided by the invention, is prepared by the following method: using water and / or an organic solvent as an extractant to extract the extract of yangtao actinidia root from yangtao actinidia root. Experiment shows that the extract of yangtao actinidia root can effectively inhibit the activity of fatty acid synthase. The inhibition kinetic analysis shows that the inhibition of the extract of yangtao actinidia root for the fatty acid synthase and the substrates of acetylcoenzyme A and NADPH have a competitive and non-competitive mixed type relationship, but more close to the non-competitive relationship; and the inhibition of the extract of yangtao actinidia root for the fatty acid synthase and the substrate of malonyl coenzyme A have a competitive and non-competitive mixed type relationship. The extract of yangtao actinidia root can be applied to the preparation of weight-reducing medicament and the medicament for preventing and treating cancers, and also can be widely applied as food, health product and daily chemical additive.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES

Production of fatty acid esters

Methods of producing fatty acid esters, such as fatty acid ethyl esters, from microorganisms genetically engineered to alter the expression of genes involved in fatty acid synthesis and / or ethanol production, such that a microorganism is obtained that can produce an alcohol, a fatty acid and an ester synthase in the absence of exogenously added alcohols.
Owner:GENOMATICA INC

Heterocyclic modulators of lipid synthesis

Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and / or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatits C infection, cancer and metabolic disorders.
Owner:GANNEX PHARM CO LTD

Fatty acid synthase in liver disease

Methods and compositions for detecting elevated fatty acid synthase (FAS) expression in the liver of a subject are disclosed. The detection may be of expression in liver cells per se or in a bodily fluid of a subject. Also disclosed are methods for identifying the presence or absence of liver disease or pathology in relation to elevated FAS. The disclosed methods may be practiced with various compositions comprising reagents for detecting FAS expression as described herein.
Owner:FASGEN

Yeast Cell Modified to Overproduce Fatty Acid and Fatty Acid-Derived Compounds

The present invention provides for a genetically modified yeast host cell capable of producing one or more fatty acids, or fatty acid-derived compounds, or a mixture thereof, comprising: (a) increased expression of acetyl-CoA carboxylase (such as ACC1), (b) increased expression of one or more fatty acid synthases (such as FAS1 and FAS2), and (c) optionally reduced expression of one or more enzymes involved in or in the β-oxidation pathway (such as peroxisomal transporters PXA1 and PXA2, and β-oxidation enzymes POX1, POX2, and POX3).
Owner:RGT UNIV OF CALIFORNIA

Novel compounds, pharmaceutical compositions containing same, and methods of use for same

A pharmaceutical composition comprising a phamaceurtical diluent and a compound of formula IV wherein R21═H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, —CH2OR25, —C(O)R25, —CO(O)R25, —C(O)NR25R26, —CH2C(O)R25, or —CH2C(O)NHR25, where R25 and R26 are each independently H, C1-C10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing one or more halogen atoms. R22 ═—OH, —OR27, —OCH2C(O)R27, —OCH2C(O)NHR27, —OC(O)R27, —OC(O)OR27, —OC(O)NHNH—R5, or —OC(O)NR27R28, where R27 and R28 are each independently H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, and where R27 and R28 can each optionally contain halogen atoms; R23 and R24, the same or different from each other, are C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl. Methods of using such formulations for the treatment of cancer, to effect weight loss, to treat microbially-based infections, to inhibit neuropeptide-Y and / or fatty acid synthase, and to stimulate CPT-1.
Owner:FASGEN

Inhibitor of fatty acid synthase and application thereof

The invention discloses an inhibitor of fatty acid synthase and application thereof, comprising the following active ingredients: 5 galloyl group gluconic acid, methyl gallate and quercetin-3-O-L-rhamnoside. The mass of three active ingredients in per gram of the inhibitor of fatty acid synthase are sequentially as follows: 18-20mug, 2-3mug, 1-2mug. The inhibitor of fatty acid synthase not only can be applied to preparation of weight loss drugs, preparation of anti-cancer drugs, but also can be widely applied to additives for foods, health products, as well as daily chemicals.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES

Compositions for enhancing the production of PPAR and/or PPAR-associated factors

The present inventors focused on certain nutritional compositions known to have activity of controlling blood glucose levels. These foods were administered to rats for long periods, and real-time PCR was used to analyze the expression of genes associated with lipid metabolism in the liver and adipose tissues. As a result, the present inventors found that the expression of the PPARα gene is enhanced by these foods, and that this is accompanied by suppressed expression of fatty acid synthase and enhanced expression of a group of PPARα target genes associated with fatty acid metabolism. The present inventors also confirmed the effect of these foods in enhancing the expression of PPARγ and adiponectin, and discovered that these foods have the activity of enhancing the production of PPAR and PPAR-associated factors.
Owner:UNIVERSITY OF TOKUSHIMA +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products